Silence Therapeutics SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 19, 2026, 8:05 a.m. ETView on SEC.gov
Entry into a material definitive agreement · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedSilence Therapeutics agrees to be acquired by Merck KGaA for $20.00 per ADS in cash, about $1.3 billion equity value
SCHEDULE 13G/AOct. 13, 2026, 7:15 p.m. ETView on SEC.gov
SCHEDULE 13GOct. 13, 2026, 4:05 p.m. ETView on SEC.gov
SCHEDULE 13G/AAug. 13, 2026, 11:13 a.m. ETView on SEC.gov
SCHEDULE 13D/AAug. 13, 2026, 9:55 p.m. ETView on SEC.gov
4Aug. 13, 2026, 10:07 a.m. ETView on SEC.gov
8-KAug. 12, 2026, 5:23 p.m. ETView on SEC.gov
Entry into a material definitive agreement · Other events · Financial statements and exhibits
424B5Aug. 12, 2026, 5:21 p.m. ETView on SEC.gov
424B5Aug. 10, 2026, 5:03 p.m. ETView on SEC.gov
8-KAug. 10, 2026, 7:57 a.m. ETView on SEC.gov
Regulation FD disclosure · Other events · Financial statements and exhibits
10-QAug. 10, 2026, 7:26 a.m. ETView on SEC.gov
8-KAug. 10, 2026, 7:20 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits